Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration

Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 8 Best Quality Stocks to Buy According to Hedge Funds. Gilead Sciences Inc. (NASDAQ:GILD) is one of the best quality stocks to buy according to hedge funds. On April 9, Tempus AI (NASDAQ:TEM) announced an expanded, multi-year collaboration with Gilead Sciences to accelerate Gilead’s oncology research and development pipeline. The agreement builds on previous work where Gilead utilized Tempus’ de-identified multimodal data for trial design, biomarker strategies, and health outcomes analysis.

Under this new enterprise-wide mandate, Gilead gains broader access to Tempus’ AI-driven Lens platform and dedicated analytical services across multiple cancer indications. The partnership aims to use Tempus’ vast library of real-world data to uncover biological insights that can improve clinical decision-making.

By integrating Gilead’s scientific expertise with advanced data insights, the companies seek to increase the probability of success for new cancer therapies. Patrick Loerch, SVP of Clinical Data Science at Gilead Sciences Inc. (NASDAQ:GILD), emphasized that the collaboration focuses on putting patients at the center of innovation through data-informed research. The collaboration underscores the growing role of AI and real-world evidence in modern drug development and precision medicine.

Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration
Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration

Copyright: dolgachov / 123RF Stock Photo

Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

Tempus AI Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

By aashura

Aashura is the Lead Researcher at CryptoListed.net. As a dedicated crypto investor and analyst since 2018, he specializes in creating clear, data-driven guides that help users navigate the market safely. Follow his latest insights on Twitter @[YourHandle].

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *